Publication | Closed Access

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Investigational AuroraMedicinePharmacologyPathologyBreast CancerAnti-cancer AgentCancer TreatmentOncologyFive-arm Phase 2Lung Cancer